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Delphine Sculier1*, Angèle Gayet-Ageron2, Manuel Battegay3, Matthias Cavassini4, Jan Fehr5, Cedric Hirzel6,
Patrick Schmid7, Enos Bernasconi8, Alexandra Calmy1 and for the Swiss HIV Cohort Study
Abstract
Background: Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy.
It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine
the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil (TDF)/emtricitabine (FTC) co-formulation within the
Swiss HIV Cohort Study and to assess its effectiveness and safety over a 24 months period.
Methods: All individuals enrolled in the Swiss HIV Cohort Study who initiated a RPV/TDF/FTC co-formulation between
April 2013 and March 2014 were included. Primary outcomes were the HIV-RNA viral load (copies/mL) and CD4 cell
count (cells/mm3) at 6, 12 and 24 months. Reasons for a switch to RPV/TDF/FTC were evaluated through a standardized
questionnaire. We also assessed discontinuation and reasons for discontinuation of RPV/TDF/FTC until October 30, 2015.
Results: Of 644 individuals who started the RPV/TDF/FTC co-formulation, only 7.5% were treatment-naïve. At 24 months,
viral suppression (HIV-RNA <50 copies/mL) was achieved in 100% and 96.7% of cART-naïve and cART-experienced
patients respectively. The switch to RPV was mainly done for simplification (44.6%) and to overcome central nervous
system toxicity symptoms due to efavirenz (24%). Six months after switch, 74.8% of patients reported an improvement
of psycho-neurological symptoms with continued improvement at 12 months for almost 80%. However, one quarter of
patients reported a discontinuation of RPV/TDF/FTC on October 30, 2015 after a median time of 18.4 months.
Reasons for discontinuation included physician decision (5.3%) and side-effects (3.9%) mainly related to the central nervous
system and to renal toxicity.
Conclusion: The RPV/TDF/FTC co-formulation was safe and effective throughout 24 months of follow-up but
barely prescribed for HIV-naïve patients. Despite excellent virological suppression among both treatment-naïve
and -experienced patients, we observed a high rate of treatment discontinuation.
Keywords: HIV-1, Rilpivirine, First-line regimen, Treatment simplification, Virological response, Safety
Background
The combination of rilpivirine (RPV), tenofovir disoproxil
(TDF) and emtricitabine (FTC) has demonstrated non-
inferior efficacy in randomized controlled trials compared
to efavirenz (EFV)-based regimens among HIV-infected,
treatment-naïve patients with a baseline viral load of less
than 105 copies/mL [1–4]. RPV/TDF/FTC has also dem-
onstrated efficacy in interventional [5] and observational
[6–11] studies among treatment-experienced virologically
suppressed patients switching to RPV. Current strategies
with combined antiretroviral treatment (cART) focus
on efficacy and safety in an aging HIV population with
multiple comorbidities requiring additional treatments
[12]. In this setting, RPV offers the advantages of few
drug-drug interactions [13] and a favourable toxicity
profile with a low incidence of grade 2–4 side-effects
[14, 15]. In particular, fewer discontinuations due to
central nervous system (CNS) adverse events in patients
receiving RPV were reported compared to patients on
EFV-based regimens [16]. Of note, EFV-related CNS tox-
icity has prompted its removal as a first-line regimen from
several international guidelines in favour of integrase inhibi-
tors, protease inhibitors [17] or RPV [18]. An improvement
of lipid parameters was also observed with RPV compared
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to EFV or protease inhibitors, with a decrease in total and
low-density lipoprotein cholesterol and triglycerides [4, 5].
RPV, co-formulated with TDF and FTC in a single tablet,
was initially approved in Switzerland on April 1, 2013, for
the treatment of HIV-naïve patients with a viral load
less than 105 copies/ml. Our experience suggested that
the RPV/TDF/FTC co-formulation was used among
virologically suppressed cART-experienced patients in
a switch strategy, either to reduce adverse events due
to the current regimen or for treatment simplification.
We sought to evaluate the reasons for the prescription,
as well as for discontinuation, of the RPV/TDF/FTC
co-formulation in participants in the Swiss HIV Cohort
Study (SHCS) after it entered the Swiss market. In
addition, we assessed its effectiveness and safety at 6 (M6),
12 (M12) and 24 months (M24) post-initiation under rou-
tine clinical conditions.
Methods
Study design and patient population
We conducted a prospective analysis among all HIV-1
infected adults ≥18 years old participating in the SHCS
who received at least one dose of the RPV/TDF/FTC co-
formulation between April 1, 2013, and March 31, 2014.
The SHCS is a multicentre prospective study established
in 1988 and continuously enrolling HIV-infected individ-
uals [19]. In brief, patients receive HIV care at one of the
7 outpatient clinics of the SHCS (Basel, Bern, Geneva,
Lausanne, Lugano, St. Gallen, Zurich), at participating re-
gional hospitals, or from collaborating private physicians.
Follow-up visits are scheduled on a 6-monthly basis and
include physical assessment, adherence check, review of
medical conditions and drug prescriptions, as well as
laboratory examinations [20]. Approximately 75% of all
HIV infected patients on cART in Switzerland are followed
within the SHCS network [21]. The scientific board of
the SHCS approved this prospective analysis and all pa-
tients signed an informed consent form before enrolment
in the SHCS.
Variables
Primary outcomes assessed treatment effectiveness through
the HIV-RNA viral load (copies/mL) and CD4 cell count
(cells/mm3) measured at M6, M12 and M24 following
initiation of the RPV/TDF/FTC co-formulation. We de-
fined virological suppression as HIV-RNA <50 copies/mL.
Secondary outcomes assessed treatment safety and used total
cholesterol (mmol/L), high-density lipoprotein (mmol/L),
triglycerides (mmol/L), alanine aminotransferase (UI/L),
creatinine (μmol/L), and the estimated glomerular function
rate (eGFR) (ml/min/1.73 m2) calculated according to the
Modification of Diet in Renal Disease equation, as well as
body mass index (kg/m2). Sociodemographic and clinical
data were prospectively collected as part of the SHCS 6-
monthly assessments at the time of initiation of the RPV/
TDF/FTC co-formulation (referred to as baseline) and at
M6, M12 and M24.
Reasons for switching to RPV/TDF/FTC were collected
retrospectively. From January 1, 2015, onwards, the HIV
Cohorts Data Exchange Protocol (HICDEP) coding [22]
was used to document treatment switches in the SHCS
database. However, before this date, treating physicians did
not have the possibility to code regimen changes intended
to simplify treatment. To obtain these data, we conducted a
survey among treating physicians of all patients included in
our study. We created a standardized questionnaire with a
closed list of reasons for switching, which was first evalu-
ated to assess its reliability among 6 physicians at the HIV
unit of Geneva University Hospitals. The questionnaire was
then sent to all physicians participating in the SHCS
who had switched their patients to the RPV/TDF/FTC
co-formulation. When physicians declared the reason
for the switch as “toxicity, predominantly from CNS”,
they were asked to give the exact reasons from a list of
CNS-specific symptoms: i) symptoms of depression; ii)
sleep disturbances/insomnia; iii) abnormal dreams; iv)
dizziness/vertigo; v) fatigue/tiredness; and vi) other.
Physicians were also required to document CNS symp-
toms at M6 and M12 after the switch as “worsening”,
“stable”, “improvement”, “not available” or “other”.
In addition, we assessed a cross-section of patients who
had discontinued the RPV/TDF/FTC co-formulation within
M24 post-treatment initiation in both the treatment-naïve
and -experienced groups and the reasons for discontinu-
ation according to the HICDEP coding registered in the
SHCS database.
Statistical analysis
We differentiated two groups of patients: those who started
RPV/TDF/FTC as a first-line regimen (cART-naïve
patients) and those who switched from any cART regimen
to RPV/TDF/FTC (cART-experienced patients).
We assessed if virological suppression were different
across the 3 time-points (M6, M12 and M24) compared
to baseline values among cART-experienced and among
cART-naïve patients separately. To take into account the
repetition of measurement in the same subject, we devel-
oped a generalized estimating equation using the binomial
family, and exchangeable correlation structure. All models
were adjusted for gender, age, history of AIDS event, HCV
and HBV positivity. Then we used a linear multilevel model
with a random effect on the patient to compare the evolu-
tion of the CD4 count across the 3 time-points compared
to baseline values first among cART-experienced then
among cART-naïve patients. We adjusted both models
for the same variables described above plus the CD4 nadir
(<50, 50–99, 100–199, 200–349, 350–499 and > = 500) and
viral load (<= or >50 copies/mL). For safety parameters, we
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performed linear multilevel models with a random effect
on the patient to compare the evolution of each parameter
across the 3 time-points compared to baseline values. Again
we performed the analyses separately in cART-experienced
then in cART-naïve patients, and adjusted for gender,
age, history of AIDS event, HCV and HBV positivity.
We repeated the three models assessing the evolution
of lipids (one model for cholesterol, triglycerides and
finally HDL-cholesterol) across the 3 time-points compared
to baseline values in the subgroup of cART-experienced
patients previously treated with 2 NRTIs and one PI.
P values were calculated from generalized estimating
equation (for viral load) and linear multilevel models (CD4,
ALAT, creatinine, eGFR, cholesterol, triglycerides, HDL-
cholesterol and BMI) comparing data at M6, M12 and
M24 to baseline among cART-naïve then among cART-
experienced patients, after adjustment for confounders
described above.
Finally, we reported the proportions of cART-experienced
and -naïve patients who discontinued the RPV/TDF/FTC
co-formulation before October 30, 2015, and described the
reasons.
All P values reported were two-sided and the level of
significance was set at 0.05. Statistical analyses were
conducted in STATA software, version 14 (StataCorp LP,
College Station, TX, USA).
Results
Baseline characteristics of patients initiating RPV/TDF/FTC
co-formulation
Between April 1, 2013, and March 31, 2014, 644 HIV-
infected patients enrolled in the SHCS started the new
RPV/TDF/FTC co-formulation. Most were male (70%; 451/
644), Caucasian (73.9%; 476/644), and men who have sex
with men (MSM) (47.7%; 307/644). Mean duration of HIV
infection was 11 years (± standard deviation [SD]: 7.8) and
mean age, 45.8 years (± 11.0 years); mean CD4 cell count at
baseline and mean CD4 nadir were 637 (± 271) and 283
cells/mm3 (± 186), respectively. Among the 644 patients,
48 (7.5%) were cART-naïve at initiation of the RPV/TDF/
FTC co-formulation, representing 10.5% of the total
number of HIV-naïve patients enrolled in the SHCS and
initiated cART during the same time period (n = 456).
The baseline characteristics of patients initiating the
co-formulation are shown in Table 1 and are presented
for cART naïve and experienced patients. Among cART
experienced patients, 44 (7.4%) were not fully virologically
suppressed (HIV-RNA > 50 copies/mL, mean HIV-RNA
16629 copies/mL) at the time of the switch.
Reasons for a switch to RPV/TDF/FTC in cART-experienced
patients
The study questionnaire was sent to the SHCS treating
physicians in November 2014. At that time, we had
identified 598 patients who were switched to RPV/
TDF/FTC during the study period. Four patients were
excluded as one did not receive the RPV/TDF/FTC co-
formulation and 3 were cART-naïve according to the
treating physicians. The non-response rate was 9.5% (57/
598 questionnaires). For these 57 patients, as well as two
additional patients identified later and without a question-
naire, we retained the reason for the switch as registered
in the SHCS database. The mean duration of cART treat-
ment at the time of switch was 8.7 years (SD: ±5.9). Before
switching, 47.8% (285/596) of cART-experienced patients
were on a non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based regimen, 26.2% (156/596) were on a
protease inhibitor-based regimen, and 9.7% (58/596)
were on an integrase inhibitor-based regimen. Of those
on a NNRTI regimen, two thirds (192/285) were on EFV.
Regimens before switch and reasons for switch are pre-
sented in Table 2. Treatment simplification (266/596; 44.6%)
and CNS toxicity (143/596; 24.0%) were the two main rea-
sons for switch.
CNS toxicity was the reason for the switch for 126
patients on an EFV-based regimen (65.6%; 126/192) with a
description of symptoms available for 123 patients (Table 3).
Among these, 60.2% (74/123 patients) had more than one
symptom, and a total of 197 CNS adverse events were
reported: insomnia/sleep disturbances (26.9%; 53/197);
abnormal dreams (18.8%; 37/197); depression (17.3%;
34/197); dizziness (15.2%; 30/197); fatigue/tiredness
(13.7%; 27/197); and other reasons (8.1%; 16/197). Six
months after the switch from EFV to RPV, 74.8% (92/123)
of patients reported an improvement of CNS symptoms,
14.6% (18/123) reported a stable condition and 3.2% (4/
123) described worsening CNS side effects. Continuous
improvement in CNS symptoms at M12 was reported for
78.3% of patients for whom we had data (72/92) while
condition remained stable for 6.5% (6/92) of patients.
Effectiveness and safety of the RPV/TDF/FTC co-
formulation
Effectiveness and safety variables over time are presented
both for treatment-naïve and –experienced patients in
Table 4. Viral suppression (HIV-RNA < 50 copies/mL)
was achieved among 93.8%, 97.6% and 100% of the cART
naive patients at M6, M12 and M24 respectively (P < 0.001).
At M24, 13 patients in the cART experienced group did not
meet the criteria for virological suppression, i.e. HIV-
RNA <50 /mL. These 13 patients were switched mostly
from a PI regimen (46%, 6/13) and from a NNRTI regimen
(38.5%, 5/13). Genotype was available for the 6 patients fail-
ing with an HIV-RNA ≥ 200 copies/mL: 3 patients had a
mutation conferring resistance to RPV at the time of viro-
logical failure, either 138A/K, 188 L or 221Y mutation. One
of these 3 patients was not fully suppressed and already had
developed a 188 L mutation at the time of the switch to
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RPV. Figure 1 shows the number of cART naive and expe-
rienced patients discontinuating RPV/TDF/FTC combin-
ation for virological failure or other reasons.
CD4 count significantly increased at M6, at M12 and
at M24 compared to baseline values in both cART naive
and experienced patients (Table 4).
For safety, we found that creatinine values significantly
increased across the 3 time-points, M6, M12 and M24,
in cART-experienced patients (P < 0.001) but not in cART-
naive patients. However, the creatinine clearance (or eGFR)
decreased over time in both groups. Total cholesterol, tri-
glycerides and HDL-cholesterol significantly decreased over
time among cART-experienced patients (Table 4). When
considering the subgroup of patients on PI-based regimen
before the switch to RPV/TDF/FTC, cholesterol decreased
significantly at M6 (mean 4.64 ± 0.96 SD, median 4.5)
and M12 (4.64 ± 0.94, 4.55) compared to baseline values
(5.09 ± 0.98 SD, median 5.01, p < 0.001). Similarly, HDL-
cholesterol decreased significantly at M6 (1.25 ± 0.37 SD,
median 1.17) and M12 (1.26 ± 0.38 SD, median 1.20) com-
pared to baseline values (1.31 ± 0.40 SD, median 1.20,
p = 0.004). Triglycerides decreased significantly across
time (M6: 1.41 ± 1.01 SD, median 1.20; M12: 1.40 ± 1.07
SD, median 1.12) compared to baseline (1.73 ± 1.21 SD,
median 1.50, p < 0.001) but at M24 values were not sig-
nificantly different from those at baseline (1.50 ± 1.20,
1.10, p = 0.516).
Follow-up on October 30, 2015
On October 30, 2015, we assessed all patients who initiated
a RPV/TDF/FTC co-formulation between March 2013 and
April 2014. The median follow-up time since RPV/TDF/
FTC initiation was 18.4 months (interquartile range: 14.0–
21.9). Overall, 166/644 (25.8%) patients had discontinued
the RPV/TDF/FTC co-formulation on October 30, 2015
(Table 5).
Besides treatment failure as described above, the most
common reasons provided for discontinuation were
Table 1 Demographic, clinical, immunological and virological baseline characteristics of patients initiating RPV/TDF/FTC co-formulation
between April 1, 2013, and March 31, 2014
Baseline characteristics Total cART-naïve patients cART-experienced
patients
(n = 596)
(n = 644) (n = 48)
Mean age, years (±SD, median) 45.8 (±11.1, 46) 42.3 (±11.3, 44.5) 46.1 (±11.0, 46)
Male gender, n (%) 451 (70.0) 41 (85.4) 410 (68.8)
HIV transmission group, n (%)
MSM 307 (47.7) 29 (60.4) 278 (46.6)
Heterosexual 260 (40.4) 14 (29.2) 246 (41.3)
Intravenous drug use 44 (6.8) 2 (4.2) 42 (7.1)
Othera 14 (2.2) 2 (4.2) 12 (2.0)
Unknown 19 (2.9) 1 (2.0) 18 (3.0)
Ethnicity, n (%)
White 476 (73.9) 37 (77.1) 439 (73.7)
Black 129 (20.0) 6 (12.5) 123 (20.6)
Hispano-American 18 (2.8) 4 (8.3) 14 (2.3)
Asian 20 (3.1) 1 (2.1) 19 (3.2)
Other 1 (0.2) 0 (0) 1 (0.2)
Mean duration of HIV infection in years (±SD, median) 11.0 (±7.8, 9.8) 2.6 (±3.3, 1.5) 11.7 (±7.7, 10.6)
History of AIDS disease, n (%) 91 (14.1) 0 (0) 91 (15.3)
Mean baselineb CD4 count, cells/mm3 (±SD, median)c 637 (±271, 606) 478 (±176, 473) 650 (±273, 620)
Mean nadir CD4 count, cells/mm3 (±SD, median)d 283 (±186, 261.5) 447 (±157, 430) 270 (±182, 247)
Baselineb HIV-RNA < 50 copies/mL, n (%)c 552 (86.1) 2 (4.2)e 549 (92.6)
HBV co-infection (positive AgHBs), n (%) 32 (5.0) 0 (0) 32 (5.4)
HCV co-infection (positive HCV-RNA), n (%) 35 (5.4) 1 (2.1) 34 (5.7)
aOther = blood products, perinatal transmission, other
bBaseline = at time of initiation of or switch to RPV/TDF/FTC co-formulation
cMissing data (n = 641, 48/48 available in naïve, 593/596 in experienced)
dMissing data (n = 640, 47/48 available in naïve, 593/596 in experienced)
eTwo cART-naïve patients started treatment with an HIV-RNA <50 copies/mL: one because of anxiety related to HIV-infection, the other was taking a combination
of tenofovir and emtricitabine intermittently without his physician knowledge. We still considered the latest as treatment-naïve of cART regimen
cART combined antiretroviral treatment, MSM men who have sex with men, SD standard deviation, HBV hepatitis B virus, HCV hepatitis C virus
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unknown (62/644; 9.6% of all patients); physician deci-
sion with no reason specified (34/644; 5.3%); patient re-
quest (12/644; 1.9%); and CNS toxicity (10/644; 1.6%).
Among the 10 patients who discontinued RPV/TDF/
FTC co-formulation for CNS side effects, all were
cART-experienced patients with 3 of them previously
receiving EFV and who had already switched to RPV/
TDF/FTC for the same reason. There were no deaths
among the study population. Of the 166 discontinua-
tions, more than half (n = 92; 55.4%) had discontinued
the RPV/TDF/FTC co-formulation for an integrase
inhibitor-based regimen. Of these switches, 44.9% (45/
92) switched to co-formulations including dolutegravir
or elvitegravir.
Discussion
We demonstrated that rilpivirine, tenofovir disoproxil
and emtricitabine in a fixed dose combination is an ef-
fective cART regimen in both treatment-experienced
and -naïve patients under routine clinical conditions,
although RPV was rarely used in naïve patients. Ninety-six
percent of treatment-experienced patients and 100 % of
treatment-naïve patients were virologically suppressed at
M24. Our findings are similar to clinical trials that showed
84–86% of virological success for RPV/TDF/FTC at M12
[3, 4] and 84% at M24 [23] in naïve patients, and 85.8% of
virological success for RPV at M12 in experienced patients
[5]. Our results are also consistent with observational
studies assessing a treatment switch to RPV (>93% of
virological success of RPV at M12) [6, 7], but none of
them assessed the use of RPV among naïve patients
under routine clinical care. Only one observational study
reported a lower proportion of virological suppression at
M12; results were explained by an inappropriate switch to
a RPV-containing regimen in patients with previous viro-
logical failure and by missing data [11]. In our study, 13
treatment-experienced patients had an HIV-RNA above
50 copies/ml at M24. We were able to obtain genotypic
data in the 6 patients failing with an HIV-RNA ≥ 200 cop-
ies/mL: 3 patients carried 138A/K, 188 L or 221Y muta-
tions at the time of failure, mutations that are known to
confer resistance to RPV [24]. One patient had a detect-
able viral load and had already developed a 188 L muta-
tion at the time of switch and should have not received
the RPV/TDF/FTC combination. The rate of confirmed
treatment failure was therefore very low in our study and
Table 2 Previous regimens at time of switch and main reasons
for switch among the 596 cART-experienced patients initiating a
RPV/TDF/FTC co-formulation
N (%)
ART regimen at switch
2 NRTIs + EFV 192 (32.2)
2 NRTIs + NVP or ETV 93 (15.6)
2 NRTIs +1 PI 156 (26.2)
2 NRTIs +1 INSTI 58 (9.7)
Triple nuke regimen 44 (7.4)
Other 29 (4.9)
Unknown 24 (4.0)
Main reasons for switch
Simplification 266 (44.6)
CNS toxicity 143 (24.0)
Physician decision 46 (7.7)
Gatrointestinal/liver toxicity 42 (7.0)
Abnormal fat distribution/dyslipidemia/concern
of cardiovascular disease
38 (6.4)
Other toxicities (including endocrine, haematological,
kidney, muscle, skin)
26(4.4)
Patient wish/decision 20 (3.4)
Drug interaction 6 (1.0)
Treatment failure 1 (0.2)
Unknown 8 (1.3)
RPV/TDF/FTC rilpivirine/tenofovir/emtricitabine, cART combined antiretroviral
treatment, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside
reverse transcriptase inhibitor, EFV efavirenz, NVP nevirapine, ETV etravirine, PI
protease inhibitor, INSTI integrase strand transfer inhibitor
Table 3 Central nervous system (CNS) adverse events experienced
by the 123 patients on EFV-based regimens reporting CNS
symptoms prior to switch and change over time on RPV/TDF/
FTC co-formulation
N (%)
CNS adverse events on previous
EFV-based regimens
197 (74 patients
with > 1 symptoms)
Insomnia/sleep disturbances 53 (26.9%)
Abnormal dreams 37 (18.8%)
Symptoms of depression 34 (17.3%)
Dizziness/vertigo 30 (15.2%)
Fatigue/tiredness 27 (13.7%)
Other 16 (8.1%)
Change in CNS symptoms reported
by patients at 6 months after switch
from EFV to RPV
123
Worsening condition 4 (3.3%)
Stable condition 18 (14.6%)
Improved condition 92 (74.8%)
Other/unknown 9 (7.3%)
Further change in CNS symptoms at
12 months after switch from EFV to
RPV in those who improved at M6
92
Worsening condition 6 (6.5%)
Stable condition 72 (78.3%)
Improved condition 13 (14.1%)
Other/unknown 1 (1.1%)
CNS central nervous system, EFV efavirenz, RPV rilpivirine, M6 month 6
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Table 4 Efficacy and safety parameters (mean values ±standard deviation, median) at M6, M12 and M24 after initiation (baseline) of
a RPV/TDF/FTC co-formulation among cART-naïve and cART-experienced patients
Baseline† M6†† M12††† M24†††† P value over time*
Viral load (copies/mL), n (%)
cART-naïve
<50 2 (4.2)¥ 45 (93.8) 41 (97.6) 26 (100) <0.001
> = 50 46 (95.8) 3 (6.2) 1 (2.4) 0 (0)
cART-experienced
<50 549 (92.6) 562 (96.2) 514 (97.5) 380 (96.7) 0.002
> = 50 44 (7.4) 22 (3.8) 13 (2.5) 13 (3.3)
CD4 count (cells/mm3), ±SD, median
cART-naïve 478 (±176, 473) 622 (±204, 602) 621 (±201, 581) 704 (±248, 649) 0.004
cART-experienced 650 (±273, 620) 676 (±285, 643) 681 (±286, 633) 697 (±363, 660) 0.001
ALAT (UI/L), ±SD, median
cART-naïve 31 (±18, 28) 31 (±16, 30) 31 (±16, 28) 30 (±14, 32) 0.578
cART-experienced 39 (±49, 29) 38 (±42, 29) 35 (±25, 29) 36 (±63, 28) 0.284
Creatinine (μmmol/L), ±SD, median
cART-naïve 94 (±82, 82) 88 (±15, 86) 88 (±15, 86) 91 (±13, 89) 0.887
cART-experienced 78 (±16, 77) 85 (±18, 85) 86 (±18, 86) 85 (±21, 83) <0.001
eGFR (mL/min/1.73m2), ±SD, median
cART-naïve 98 (±25, 100) 90 (±20, 89) 91 (±21, 91) 90 (±26, 86) 0.008
cART-experienced 100 (±25, 96) 90 (±28, 86) 88 (±23, 85) 89 (±26, 87) <0.001
Cholesterol (mmol/L), ±SD, median
cART-naïve 4.7 (±1.0, 4.8) 4.5 (±1.0, 4.4) 4.5 (±1.0, 4.4) NA 0.270
cART-experienced 5.1 (±1.0, 5.0) 4.7 (±1.0, 4.6) 4.7 (1.0, 4.6) NA <0.001
Triglycerides (mmol/L), ±SD, median
cART-naïve 1.5 (±1.1, 1.2) 1.5 (±1.1, 1.3) 1.5 (±0.9, 1.4) 1.3 (±0.6, 1.2) 0.347
cART-experienced 1.6 (±1.3, 1.3) 1.4 (±0.9, 1.2) 1.4 (±0.9, 1.2) 1.4 (±0.9, 1.2) <0.001
HDL-cholesterol (mmol/L), ±SD, median
cART-naïve 1.2 (±0.4, 1.2) 1.2 (±0.3, 1.2) 1.1 (±0.3, 1.2) NA 0.195
cART-experienced 1.3 (±0.4, 1.3) 1.3 (±0.3, 1.2) 1.2 (±0.3, 1.2) NA <0.001
BMI (kg/m2), ±SD, median
cART-naïve 23.6 (±5.6, 22.6) 24.2 (±3.8, 23.7) 24.2 (±3.9, 23.8) 22.9 (±1.0, 22.9) 0.006
cART-experienced 24.9 (±5.3, 24.4) 24.7 (±4.0, 24.3) 24.7 (±3.9, 24.3) 24.8 (±4.6, 24.0) 0.096
†Missing data (ASAT 37/48 available in naïve patients, 565/596 in experienced; ALAT 37/48 available in naïve patients, 576/596 in experienced;
creatinine and eGFR 33/48 available in naïve patients, 463/596 in experienced; triglycerides 36/48 available in naïve patients, 540/596 in experienced;
cholesterol 36/48 available in naïve patients, 542/596 in experienced; HDL 36/48 available in naïve patients, 530/596 in experienced; weight 48/48
available in naïve patients, 574/596 in experienced; waist and hip 48/48 available in naïve patients, 563/596 in experienced; BMI 48/48 available in
naïve patients, 574/596 in experienced)
††Missing data (ASAT/ALAT/Cholesterol 48/48 available in naïve patients, 583/596 in experienced; creatinine/eGFR/triglycerides 48/48 available in naïve
patients, 578/596 in experienced; HDL/weight/BMI 48/48 available in naïve patients, 582/596 in experienced; waist and hip 48/48 available in naïve
patients, 580/596 in experienced)
†††Missing data (ASAT/ALAT 42/48 available in naïve patients, 527/596 in experienced; creatinine 42/48 available in naïve patients, 521/596 in
experienced; eGFR 41/48 available in naïve patients, 517/596 in experienced; triglycerides 41/48 available in naïve patients, 522/596 in experienced;
cholesterol 41/48 available in naïve patients, 526/596 in experienced; HDL 41/48 available in naïve patients, 525/596 in experienced; weight 44/48
available in naïve patients, 513/596 in experienced; waist 44/48 available in naïve patients, 511/596 in experienced; hip 44/48 available in naïve
patients, 510/596 in experienced; BMI 44/48 available in naïve patients, 513/596 in experienced)
††††Missing data (ALAT 15/48 available in naïve patients, 239/596 in experienced; creatinine 14/48 available in naïve patients, 236/596 in experienced; eGFR
14/48 available in naïve patients, 235/596 in experienced; triglycerides 14/48 available in naïve patients, 232/596 in experienced; cholesterol 0/48 available in
naïve patients, 0/596 in experienced; HDL 0/48 available in naïve patients, 0/596 in experienced; weight 4/48 available in naïve patients, 158/596 in
experienced; waist 4/48 available in naïve patients, 151/596 in experienced; hip 4/48 available in naïve patients, 151/596 in experienced; BMI 4/48 available
in naïve patients, 158/596 in experienced)
*P-values from generalized estimating equation (for viral load) and linear multilevel models (CD4, ALAT, creatinine, eGFR, cholesterol, triglycerides,
HDL-cholesterol and BMI) comparing data at M6, M12 and M24 to baseline among cART-naïve and cART-experienced patients separately, after adjustment
for main confounders
RPV/TDF/FTC rilpivirine/tenofovir/emtricitabine, cART combined antiretroviral treatment, ASAT aspartate aminotransferase, ALAT alanine
aminotransferase, eGFR glomerular filtration rate, HDL high-density lipoprotein, BMI body mass index
¥Two cART-naïve patients started treatment with an HIV-RNA <50 copies/mL: one because of anxiety related to HIV-infection, the other was taking a
combination of tenofovir and emtricitabine intermittently without his physician knowledge
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detectable HIV-RNA may translate blips in viral load or
poor adherence rather than virological failure.
Among cART-experienced patients, the main reasons
for a switch to the newly marketed RPV/TDF/FTC co-
formulation were treatment simplification and CNS tox-
icity. The proportion of patients switching to RPV for
simplification is slightly lower than in other observational
studies [6, 11]. Unlike previous reports [6, 7, 11], we ac-
curately assessed the reasons for a switch to RPV with a
dedicated detailed questionnaire. Due to the retrospective
manner and a non-response rate of 9.5% to our standard-
ized questionnaire, it is possible that the simplification
reason was underreported or rather stated as “physician
decision” or “patient request”. Among those who switched
because of CNS toxicity, most were on an EFV-based
regimen. Symptoms did improve in approximately 75%
of patients 6 months after the switch with a continuous
improvement at M12. Moreover, only 3 patients switched
from EFV to RPV/TDF/FTC later discontinued RPV co-
formulation for persisting CNS side effects. While there
was no change in neurocognitive functions after EFV re-
placement for a PI drug in a small controlled trial enrolling
16 patients [25], another observational study confirmed
improvement in neurological side-effects in almost 50% of
patients switching from an EFV-based regimen to RPV [6].
Switch from EFV to RPV seems therefore a reasonable and
sustainable option for patients experiencing CNS side
effects on EFV.
Overall, the RPV/TDF/FTC co-formulation was safe
and well tolerated in most patients. As shown in previous
studies [6, 7, 11], we observed a significant increase in cre-
atinine over time among our study population, but this
difference was not clinically relevant. Rilpivirine is known
to inhibit the creatinine transporter in the proximal renal
tubule [13]. Similarly to other studies [6, 7, 11], we did ob-
serve a significant change in the lipid profile of treatment-
experienced patients after the switch to RPV/TDF/FTC.
This was also true for the subset of patients previously on
PI. However, there was no effect of RPV/TDF/FTC on
lipid profile over time among cART-naïve patients; this
may be due to the small number of treatment naïve sub-
jects included and the lack of power to detect an effect.
Despite good results for the effectiveness and tolerability
of the RPV/TDF/FTC co-formulation, a quarter of patients
changed their ART regimen, mainly upon physician deci-
sion, after a mean time of 18.4 months. This is much shorter
than the reported mean duration of patients on first- and
second-line newer cART regimens (4.6 and 3.9 years,
respectively) in the 2008–2011 period as described in
the HIV Outpatient Study [26]. We hypothesized that
there is a low confidence in the RPV genetic barrier
among treating physicians [27], particularly when compared
to newer once-daily, inhibitor-based co-formulation regi-
mens, the latest being marketed in Switzerland only 2 years
after the RPV/TDF/FTC co-formulation. The need for a
fatty meal intake may be also a barrier to the large-scale
prescription of this regimen although the acceptability of
food constraint was not formally assessed in our study.
Finally, less than 5% of patients discontinued the RPV/
TDF/FTC co-formulation due to side-effects, mainly CNS-
Fig. 1 Flowchart of patients initiating RPV/TDF/FTC co-formulation, discontinuation and treatment failures. *Discontinuation for other reasons than
virological failure Vl viral load, cART combined antiretroviral therapy
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related symptoms and kidney toxicity. Neuropsychiatric
adverse events due to RPV were described in up to 27% of
naïve patients receiving 48 weeks of RPV in clinical trials,
but discontinuation was rare [16]. In our study, discontinu-
ation of RPV for CNS toxicity (1.6%) was much lower than
discontinuation of EFV for the same reason (65.6%).
It is also lower than discontinuation rates reported on
dolutegravir in routine clinical settings, which ranged
between 3.4% and 6% [28].
Although we included a small number of cART-naïve
patients, our study is the first to report on treatment
outcomes up to 24 months under routine clinical condi-
tions in this population. This may provide the necessary
confidence to clinicians to prescribe the RPV/TDF/FTC
co-formulation to HIV-naïve patients if the virological
criteria are met, and providing that the patient consents
to comply with the dietary restrictions.
Our study has several limitations. First, the standardized
questionnaire on the reasons for a switch to the RPV/TDF/
FTC co-formulation was retrospective and therefore subject
to recall bias, particularly regarding the possible over-
reporting of CNS toxicity symptoms and their improve-
ment after a switch from EFV to RPV. Second, the study
population was mainly Caucasian, male, and MSM, which
renders more difficult the generalizability of our results to
under-represented transmission groups. Finally, we did not
compare initiation to RPV/TDC/FTC co-formulation to
starts and switches to alternative regimens during the same
time period.
Conclusions
The use of RPV is safe and effective under routine clinical
conditions, both in a switch strategy and in naïve patients.
Our study supports policy changes made in Switzerland in
October 2014 to use RPV for cART-experienced virologic-
ally suppressed patients. RPV demonstrates a favourable
neurological toxicity profile with most patients experien-
cing CNS side effects on EFV improving after a switch to
RPV and very low discontinuation rate for CNS events
when compared to EFV or integrase inhibitor. Future
research should focus on comparing the RPV/TDF/FTC
co-formulation with newer available regimens containing
integrase inhibitors in a switch strategy, including an
assessment of cost-effectiveness. The reasons for early
discontinuation of RPV/TDF/FTC co-formulation based
on physician decision in the SHCS should also be further
explored.
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